Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for fondaparinux sodium

  1. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

  2. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  3. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    heparin (UFH)• fondaparinux sodium• direct-acting anticoagulant• vitamin K antagonists C: standard-dose:• LMWH UFH• fondaparinux...

  4. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    standard-dose:• low molecular weight heparins• unfractionated heparins• fondaparinux sodium• direct-acting anticoagulant• vitamin K...

  5. Research recommendations

    pregabalin and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide. CG137/1